These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 19649784)
1. Structure-based design of enzyme inhibitors and receptor ligands. Kubinyi H Curr Opin Drug Discov Devel; 1998 Jul; 1(1):4-15. PubMed ID: 19649784 [TBL] [Abstract][Full Text] [Related]
2. Combinatorial and computational approaches in structure-based drug design. Kubinyi H Curr Opin Drug Discov Devel; 1998 Jul; 1(1):16-27. PubMed ID: 19649785 [TBL] [Abstract][Full Text] [Related]
3. Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. Zauhar RJ; Moyna G; Tian L; Li Z; Welsh WJ J Med Chem; 2003 Dec; 46(26):5674-90. PubMed ID: 14667221 [TBL] [Abstract][Full Text] [Related]
4. Exploring experimental sources of multiple protein conformations in structure-based drug design. Damm KL; Carlson HA J Am Chem Soc; 2007 Jul; 129(26):8225-35. PubMed ID: 17555316 [TBL] [Abstract][Full Text] [Related]
5. E-novo: an automated workflow for efficient structure-based lead optimization. Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372 [TBL] [Abstract][Full Text] [Related]
6. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors. Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716 [TBL] [Abstract][Full Text] [Related]
7. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273 [TBL] [Abstract][Full Text] [Related]
8. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin. Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086 [TBL] [Abstract][Full Text] [Related]
9. Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design. Nisius B; Rester U J Chem Inf Model; 2009 May; 49(5):1211-22. PubMed ID: 19413347 [TBL] [Abstract][Full Text] [Related]
10. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. Tintori C; Corradi V; Magnani M; Manetti F; Botta M J Chem Inf Model; 2008 Nov; 48(11):2166-79. PubMed ID: 18942779 [TBL] [Abstract][Full Text] [Related]
11. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Heckmann D; Meyer A; Laufer B; Zahn G; Stragies R; Kessler H Chembiochem; 2008 Jun; 9(9):1397-407. PubMed ID: 18481343 [TBL] [Abstract][Full Text] [Related]
12. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. Lucas S; Heim R; Negri M; Antes I; Ries C; Schewe KE; Bisi A; Gobbi S; Hartmann RW J Med Chem; 2008 Oct; 51(19):6138-49. PubMed ID: 18763754 [TBL] [Abstract][Full Text] [Related]
13. Comparative studies on inhibitors of HIV protease: a target for drug design. Jayaraman S; Shah K In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129 [TBL] [Abstract][Full Text] [Related]
14. Strategies for generating less toxic P-selectin inhibitors: pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits. Ananthula RS; Ravikumar M; Pramod AB; Madala KK; Mahmood SK J Mol Graph Model; 2008 Nov; 27(4):546-57. PubMed ID: 18993099 [TBL] [Abstract][Full Text] [Related]
15. Construction of a three-dimensional pharmacophore for Bcl-2 inhibitors by flexible docking and the multiple copy simultaneous search method. Zheng CH; Zhou YJ; Zhu J; Ji HT; Chen J; Li YW; Sheng CQ; Lu JG; Jiang JH; Tang H; Song YL Bioorg Med Chem; 2007 Oct; 15(19):6407-17. PubMed ID: 17629704 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and optimization of peptidomimetics as HIV entry inhibitors against the receptor protein CD4 using STD NMR and ligand docking. Neffe AT; Bilang M; Meyer B Org Biomol Chem; 2006 Sep; 4(17):3259-67. PubMed ID: 17036114 [TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors. Vaidya M; Weigt M; Wiese M Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462 [TBL] [Abstract][Full Text] [Related]
18. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. Steuber H; Zentgraf M; Gerlach C; Sotriffer CA; Heine A; Klebe G J Mol Biol; 2006 Oct; 363(1):174-87. PubMed ID: 16952371 [TBL] [Abstract][Full Text] [Related]
19. LigEvolutioner, a new strategy for modification and optimization of lead compounds in receptor/ligand complexes. Zhou P; Tian F; Shang Z Chem Biol Drug Des; 2008 Dec; 72(6):525-32. PubMed ID: 19090919 [TBL] [Abstract][Full Text] [Related]
20. Interpretation of protein/ligand crystal structure using QM/MM calculations: case of HIV-1 protease/metallacarborane complex. Fanfrlík J; Brynda J; Rezác J; Hobza P; Lepsík M J Phys Chem B; 2008 Nov; 112(47):15094-102. PubMed ID: 18975888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]